The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

Wetwittayakhlang, Panu; Tselekouni, Paraskevi; Al-Jabri, Reem; Bessissow, Talat; Lakatos, László

doi:10.3390/jcm12062432

Cited by 7 publications

(2 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the management and treatment of IBD have significantly improved over the years. Advancements in medical therapies, including immunomodulators and biological agents, have allowed for better control of inflammation in the gastrointestinal tract [ 29 , 30 ]. These treatments could not only help manage IBD symptoms but also reduce the risk of CRC development.…”

Section: Discussionmentioning

confidence: 99%

Does Elderly-Onset Inflammatory Bowel Disease Increase Risk of Colorectal Cancer? A Systematic Review and Meta-Analysis

Zamani,

Alizadeh-Tabari

2023

JCM

View full text Add to dashboard Cite

Background: Although younger adults with inflammatory bowel disease (IBD) are known to have an increased risk of developing colorectal cancer (CRC), the impact of IBD on CRC risk in elderly patients is not yet fully understood. Therefore, we conducted this systematic review and meta-analysis to address this knowledge gap. Methods: We thoroughly searched Embase, PubMed, and Scopus, covering the literature from inception to 31 August 2023, in any language. We enrolled population-based cohort studies that appraised the risk of CRC development in elderly patients (≥60 years) with IBD as compared to the non-IBD population. Our meta-analysis provided pooled relative risk (RR) with 95% confidence intervals (CIs) using a random-effect model. Results: Out of 3904 citations, 3 eligible cohort studies were ultimately included, reporting 694 CRC events in 35,187 patients with IBD. According to analysis, the risk of developing CRC did not increase in patients with elderly-onset IBD (RR = 1.17 [95% CI: 0.86–1.47]; I2 = 62.6%). This lack of a significant association was observed in both patients with Crohn’s disease (RR = 1.28 [95% CI: 0.88–1.69]) and ulcerative colitis (RR = 0.99 [95% CI: 0.90–1.09]) (p for interaction = 0.166). Conclusion: Our findings revealed no significant increase in the risk of incident CRC in patients with elderly-onset IBD, suggesting that intense screening of these patients for CRC may not be necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Does Elderly-Onset Inflammatory Bowel Disease Increase Risk of Colorectal Cancer? A Systematic Review and Meta-Analysis

Zamani,

Alizadeh-Tabari

2023

JCM

View full text Add to dashboard Cite

show abstract

“…Disease management and reducing drug-related hazards should coexist in individualized treatment programs [36]. To balance the hazards of IBD medication and cancer management, patients with IBD and concurrent cancer must thoroughly assess their treatment options [37][38][39][40][41]. To improve patient outcomes, gastroenterologists and oncologists must work closely [42][43][44][45][46][47][48].…”

Section: Table 3: Medication Of Inflammatory Bowel Diseasementioning

confidence: 99%

Advancements in Inflammatory Bowel Disease: A Narrative Review of Diagnostics, Management, Epidemiology, Prevalence, Patient Outcomes, Quality of Life, and Clinical Presentation

Muzammil,

Fariha,

Patel

et al. 2023

Cureus

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is a chronic, immune-mediated disorder that impacts the gastrointestinal tract. Significant advancements in the diagnosis and treatment of IBD have been made during the past few decades, improving patient outcomes. This narrative review aims to provide an overview of recent developments in the diagnosis and treatment of IBD. Both from an evaluative and therapeutic standpoint, the management of IBD has undergone significant change. The standard of treatment for treating UC and CD patients has changed due to several medical developments. These developments include amino-salicylates, immunosuppressants, biological agents, and new therapeutics. The review also addresses the difficulties in applying these developments in clinical practice. Globally, the prevalence of IBD is rising, with Asia among the regions with the highest rates. These environments provide particular difficulties, such as poor disease knowledge, a lack of diagnostic services, and infectious IBD mimics. These issues must be resolved to diagnose and manage IBD in these populations accurately. New imaging modalities and other improvements in diagnostic methods have increased the precision and early identification of IBD. To reduce problems and improve patient outcomes, healthcare professionals treating patients with IBD must work effectively as a team. An extensive summary of current developments in the diagnosis and treatment of IBD is given in this narrative review. It draws attention to the therapeutic possibilities, difficulties, and uncertainties of integrating these developments into clinical practice. By keeping up with these changes, healthcare practitioners can better care for patients with IBD and improve their quality of life.

show abstract

How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?

Wetwittayakhlang,

Kotrri,

Bessissow

et al. 2024

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer

Cited by 7 publications

References 124 publications

Does Elderly-Onset Inflammatory Bowel Disease Increase Risk of Colorectal Cancer? A Systematic Review and Meta-Analysis

Does Elderly-Onset Inflammatory Bowel Disease Increase Risk of Colorectal Cancer? A Systematic Review and Meta-Analysis

Advancements in Inflammatory Bowel Disease: A Narrative Review of Diagnostics, Management, Epidemiology, Prevalence, Patient Outcomes, Quality of Life, and Clinical Presentation

How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?

Contact Info

Product

Resources

About